"An 18-fold increase in non-face-to-face prescriptions for obesity treatment injection 'Saxenda'"

It was found that the prescription for the injection-type obesity treatment "Saxenda" through non-face-to-face treatment increased 18 times from the end of last year.

According to data from the Health Insurance Review and Assessment Service received by Jeon Jin-sook of the Democratic Party of Korea of the National Assembly's Health and Welfare Committee, the number of Saxenda prescriptions using non-face-to-face treatment increased 18.3 times from 183 in December last year to 3,347 last month.

During the same period, the number of face-to-face prescriptions increased only 1.1 times from 25,562 to 14,729.

In February, the government allowed non-face-to-face treatment of first-time patients and medical institutions above the hospital level to fill the resignation gap of majors.

Lawmaker Jeon Jin-sook urged measures to be prepared, saying that non-face-to-face treatment, which is operated in the form of a pilot project, is leading to non-essential over-treatment.